460-P: Eating Behavior among Inpatients with Type 2 Diabetes (T2D) Is Affected by Childhood Food Education

Abstract

Background: Eating abnormalities have been observed in some patients with T2D. It is also known that food preferences and habits are affected by many factors, such as childhood food education, insulin secretion (which suppresses appetite after eating meals), and appetite control by executive functions. Meanwhile, blood flow in the cerebral frontal lobe has been reported to be decreased in patients with severe hyperglycemia, which might result in impaired executive function. Objective: This cross-sectional study aimed to identify factors affecting eating behavior among inpatients with T2D. Methods: A total of 27 inpatients were requested to complete a self-administered questionnaire using a 5-point scale, consisting of the following 3 questions (Qs): (1) Do you want to eat the same thing over and over? (2) Do you feel that your appetite cannot be suppressed? (3) Do you eat meals hungrily? Further, we investigated correlations between these Qs and the following variables: body weight (BW), HbA1c levels, glucagon-stimulated changes in plasma C-peptide concentrations(ΔCPR), and baseline characteristics on admission. Results: The mean age was 68 years; mean BW on admission, 69.5 kg; mean BW at the age of 20 years, 63.4 kg; maximum BW, 79.8 kg; mean HbA1c level, 10.2%; and medianΔCPR, 1.26 ng/ml. Q1 and Q2 were positively associated with all the BWs assessed in this study (Spearman r ≧ 0.33 and 0.23, respectively), with the association between Q1 and BW being strongest at the age of 20 (r =0.463, p < 0.05). Furthermore,ΔCPR showed only a negative correlation with Q2, whereas HbA1c levels on admission were found to positively correlate with Q1 and Q3 (r ≧ 0.24). Conclusions: From the strong relationship between the used questionnaire and BW at the age of 20, eating behavior was concluded to be determined in childhood. Our study also demonstrated that insulin secretion might suppress appetite, and that poor glycemic control did not contribute to appetite suppression via executive functions. Disclosure M. Takahashi: None. T. Minami: None. A. Kameda: None. T. Yamada: None. H. Hiiragi: None. F. Yoshida: None. K. Okubo: None. Y. Terauchi: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K. K., Novo Nordisk, Sanofi, Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K. K., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk, Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Speaker’s Bureau; Self; Abbott, Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K. K., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk, Ono Pharmaceutical Co., Ltd., Sanofi, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited.